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Pulmonary Changes Induced by
Amphophilic Drugs
by Zdenek Hruban*
Administration of amphophilic drugs to experimental animals causes formation of myeloid
bodies in many cell types, accumulation of foamy macrophages in pulmonary alveoli, and pul-
monary alveolar proteinosis. These changes are the result ofan interaction between the drugs and
phospholipids which leads to an alteration in physicochemical properties of the phospholipids.
Impairment of the digestion of altered pulmonary secretions in phagosomes of macrophages re-
sults in accumulation offoam cells in pulmonary alveoli. Impairment ofthe metabolism ofaltered
phospholipids removed by autophagy induces an accumulation of myeloid bodies. In summary,
administration of amphophilic compounds causes a drug-induced lysosomal disease or gener-
alized phospholipidosis.
In recent years it is becoming increasingly ap-
parent that certain drugs administered system-
ically to man have serious side effects because of
their affinity for the lungs. The* pulmonary pa-
thology produced by these drugs has received
relatively little clinical attention because of the
insiduous and chronic nature of its development.
With increasing awareness that a large variety of
seemingly harmless drugs can induce such lung
changes, it is imperative that more rigorous
studies be carried out before such drugs are put
to clinical use. The purpose of this report is to
review a group of drugs which lead to intra-
alveolar histiocytosis.
In 1966 Greselin reported (1) that chronic ad-
ministration of a drug which inhibits cholesterol
synthesis, trans-i, 4-bis(2-chlorobenzylamino-
methyl)cyclohexane dichloride, also called AY-
9944, induces accumulation of foam cells in pul-
monary alveoli of experimental animals. In the
past six years other drugs with different phar-
macological effects were shown to produce simi-
lar pulmonary side effects. These drugs include
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the anthistaminic chlorcyclizine and its deriva-
tives (2), the hypolipidemic agents triparanol
(2,3), haloperidol (2), boxidine (2), and the already
mentioned AY-9944 (1,4), the chemotherapeutic
drug chloroquine (2), the anorectic agents chlor-
phentermine (3, 5-9), cloforex (10, 11) and fen-
fluramine (12), the tricyclic antidepressants
iprindole (13-16), 1-chloroaminotryptyline (17),
imipramine (18), and clomipramine (18), and the
coronary vasodilator 4,4'-diethylaminoethoxy-
hexestrol (19).
These drugs induce essentially similar histolog-
ical and ultrastructural changes in the lung, al-
though the time required for the appearance of
the foam cells and their quantity and size may be
quite different in various animal species
(1,7,8,12). The lungs of the treated animals in-
crease in weight (1,11) and contain whitish
plaques and nodules on gross examination (1,2).
Microscopically these plaques consist of intra-
alveolar accumulations offoam cells (1,2).
The foam cells are between 20 and 80 ,Am in
diameter (3,4,6,8) and have a centrally placed
nucleus. The cytoplasm is abundant, pale, and
finely reticulated in hematoxylin-eosin stained
sections (Fig. 1). In toluidine blue-stained Epon
August 1976 IIIsections, the foam cells are filled with numerous
round inclusions (Figs. 2 and 3). Staining of foam
FIGURE 1. Foam cells in alveolar lumina of a rat fed chlorcy-
clizine. Hematoxylin-eosin, x350.
FIGURE 2. Amorphous material and foam cells in alveolar
lumina of a rat fed chlorcyclizine for 4 weeks. Granular
pneumocytes are seen on alveolar walls. Toluidine blue,
thicksection; x450.
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FIGURE 3. Numerous foam cells in alveolar lumina of a rat fed
chlorcyclizine for 9 weeks. Toluidine blue, thick section;
x450.
cells with Baker's acid hematein for phospholip-
ids is positive, while staining with Sudan III and
by the periodic acid-Schiff method are negative
(2,6,11). Other staining reactions identify the
material in the foam cells as choline-containing
phosphoglycerides, including lecithin (11). Histo-
chemical studies reveal high activities of acid
phosphatase and P-glucuronidase, implicating the
foam cells as macrophages (6,8,13,16).
The time sequence of pulmonary changes asso-
ciated with foam cell accumulation has been
studied at light and electron microscopic levels.
The first change observed in iprindole-treated
rats is interstitial pulmonary edema associated
with degenerative changes in capillary endothelia
(16). Subsequently endothelia and alveolar
epithelia become swollen and the septa are infil-
trated by interstitial macrophages (16). The
lungs of chlorphentermine-treated rats show hy-
peremia, aggregation ofleucocytes in venules and
perivascular infiltration by monocytes during the
first week of treatment (8). In general a few
intra-alveolar macrophages appear early and be-
come progressively larger and more numerous
(2,6,11). These macrophages are derived from in-
terstitial macrophages (6,14), which in turn orig-
inate from blood monocytes (8,10). In histological
sections the alveolar lumina contain abundant
amorphous material (Fig. 2), which somewhat
resembles the material seen in alveolar pro-
teinosis (4). On ultrastructural examination the
material is identified as secretions derived from
secretory vacuoles of granular pneumocytes
(Figs. 4 and 5). It has been shown (2,9,20) that the
intra-alveolar macrophages phagocytize the se-
cretions, which are rich in dipalmytoyl lecithin
(3), and become foam cells (Figs. 3 and 6). After
3-6 weeks of treatment, the foam cells are nu-
merous (2,4,8,13).
A marked decrease in the secretory activity of
type 2 pneumocytes is observed after 9 months of
treatment (15). After 12 month of iprindole
feeding, the accumulations of foam cells are re-
placed by pale eosinophilic granular material in
the intra-alveolar spaces as a result of cellular
breakdown, and the histological picture is that of
alveolar proteinosis (15). Degeneration of
macrophages is also seen in rats treated with
AY-9944 for prolonged periods (1). If the admin-
istration of the drug is withdrawn after several
weeks of treatment, the size and the number of
foam cells will decrease in 2-3 weeks (2,6). During
this process the secretions in phagosomes of mac-
rophages are replaced by electron dense hetero-
geneous material (2) (Fig. 7).
Environmental Health Perspectives 112FIGURE 4. Concentric secretions and dense masses of tubular FIGURE 6. Portions of several alveolar macrophages filled with
figures in an alveolar lumen of a rat fed chlorcyclizine for 4 alveolar secretions from a rat treated with chlorcyclizine for
weeks. The heterogeneous mass (arrow) may be derived 9weeks. x2800.
from contents of lysosomes released into alveolar lumen.
x4800. < -;; i!. '; ':
FIGURE 5. Secretory vacuoles ofa granular pneumocyte from a
rat fed chlorcyclizine for 9weeks. x5600.
Other pulmonary cells also show striking
changes. Type 2 pneumocytes become hypertro-
phic and hyperplastic after triparanol and chlor-
cyclizine treatment (2,4) but do not show changes
after chlorphentermine treatment (6). The secre-
tory vacuoles of type 2 pneumocytes are large
(2,15). Myeloid bodies (21,22) and heterogeneous
dense bodies are found in the cytoplasm of type 1
pneumocytes (Fig. 8), ciliated bronchiolar epithe-
lia and Clara cells, smooth muscle cells, fibro-
FIGURE 7. Portion of a pulmonary macrophage from a rat
treated with chlorcyclizine for 14 weeks and allowed to re-
cover for 2 weeks. x5600.
blasts and capillary endothelia (2-4,15,16,19).
Other investigators refer to the myeloid bodies as
concentric lamellar inclusion bodies (3,6) and
membrane-bound lamellated inclusion bodies
(23). Heterogeneous dense bodies are secondary
lysosomes. Myeloid bodies are lysosomes filled
with concentric layers of myeloid membranes
August 1976 113FIGURE 8. Type I pneumocytes from a rat fed chlorcyclizine for 5 weeks. The upper cell contains numerous myeloid bodies. The
lower cell contains heterogeneous dense bodies and material resembling alveolar secretions. Portion of a macrophage is seen in
left upper corner. X15,600.
(Fig. 9), although in some cells they may contain
reticular or crystalloid structures (21,22). Such
reticular or crystalloid myeloid bodies were
found in various pulmonary cells, but not in
pulmonary macrophages (3). The drugs which in-
duce accumulations of pulmonary foam cells are
also known to induce formation of myeloid bodies
in many other cell types of various tissues
(7,22,24).
Because the inclusions in foam cells and the
myeloid bodies are modified lysosomes, knowl-
114
edge of lysosome formation by heterophagy and
by autophagy is necessary to understand their
nature (22). In autophagy, sequestering cisternae
surround a portion of the cytoplasm with or-
ganelles and form an autophagic vacuole (Fig. 9).
The thin membranes of the sequestering cisterna
are transfromed into a thick limiting membrane
of the lysosome. Hydrolytic enzymes formed in
endoplasmic reticulum are brought to the auto-
phagic vacuole within primary lysosomes. The se-
questered organelles are broken down by the
Environmental Health PerspectivesFIGURE 9. Portions oftwo liver cells from a rat fed chlorcyclizine for 5 weeks. Myeloid bodies are surrounded by a lysosomal mem-
brane. An autophagic vacuole contains sequestered endoplasmic reticulum. A mitochondrion is recognizable in a body which also
contains myeloid figures x 11,900.
hydrolytic enzymes and the autophagic vacuole
changes into a heterogeneous dense body (sec-
ondary lysosome). Further digestion leads to the
appearance of smaller homogeneous dense bodies
(residual bodies). In heterophagy, the extra-
cellular material enters the cell within pino-
cytotic vesicles and phagocytic vacuoles. Primary
lysosomes empty their enzymes into this vacuole,
and the digestion proceeds as in autophagy.
If the degradation of substrates sequestered
within lysosomes is impaired, the substrates will
accumulate, and the lysosomes will become stor-
age bodies. The impairment of lysosomal diges-
tion may have a variety of causes. Leprosy bacilli
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are known to inhibit lysosomal digestion in phag-
osomes. Human storage diseases are caused by
the absence of specific lysosomal enzymes. Mye-
loid bodies are storage bodies containing mem-
branes whose digestion is impaired by drugs (20).
The inclusions in foam cells are phagosomes stor-
ing phagocytized pulmonary secretions whose di-
gestion is impaired by drugs.
The inclusions in foam cells and myeloid bodies
are sometimes grouped together as "concentric
lamellar inclusion bodies" (3,6,9). They are, how-
ever, different structurally and etiologically
(2,15,16). The material within pulmonary macro-
phages is less densely packed and arranged in a
115less orderly fashion than are the myeloid mem-
branes within myeloid bodies (6,16). Myeloid
body is an autophagosome while the inclusion in
the macriphage is a heterophagosome. Some in-
vestigators believe that in chorphentermine
treated animals autophagy may not precede or be
increased during the formation of myeloid bodies
(3,23,25). Increased autophagy has been,
however, observed with other drugs (2,21,26).
The fact that myeloid bodies show acid phospha-
tase activity (6,21,27,28) and are lysosomes
(6,16,26,28) indicates that autophagy or
heterophagy must be involved in their formation.
Myeloid bodies are surrounded by a lysosomal
membrane and should be distinguished from mye-
loid figures lying free in the cytoplasm or on the
surface of mitochondria (22,29). Presence of mye-
loid figures protruding into mitochondria in
granular pneumocytes (30) and in cells of murine
pulmonary tumors originating from type 2 pneu-
mocytes (31) does not indicate that myeloid
figures are precursors of membrane bound secre-
tions of granular pneumocytes. The structure of
pulmonary secretions and of myeloid figures is
quite different (19) (compare Figs. 5 and 9).
Biochemical studies show that the accumula-
tion of pulmonary foam cells is associated with an
increase of lipids. Chlorphentermine treatment
leads to a twofold increase of total pulmonary
lipids in the rat (32) and to a tenfold increase of
the lipid content of pulmonary macrophages (33).
The sphingomyelin. cholesterol, and cholesterol
ester fractions are markedly increased while
phosphatidylcholine is increased fivefold (32).
Cloforex increases the cholesterol content of rat
lung by 50% and the phospholipid content five
times (1). A marked increase ofthe levels of total
phospholipids, total sterols, lyso-bisphosphatidic
acid, and desmosterol was demonstrated in the
lamellar body fraction isolated from lungs of rats
treated with diethylaminoethoxyhexestrol (19).
Desmosterol was also found in fractions contain-
ing myeloid bodies induced by inhibitors of cho-
lesterol synthesis (27,34). Finally, it has been
demonstrated that the drugs inducing foam cell
accumulation have a very high affinity for the
lung (4,33,35-37).
The factors which should be considered in the
pathogenesis ofintra-alveolar foam cell accumula-
tion are: increased production of surfactant and/
or decreased clearance of pulmonary macro-
phages (2,4,15); lipolytic action of the drugs with
subsequent excretion oflipids by the lung (11); in-
hibition of fusion of primary lysosomes with
phagocytic vacuoles (38); accumulation of
cholesterol precursors in macrophages (1,2,4,27);
formation of abnormal "foreign" phospholipids
which can not be eliminated by normal pathways
(39); interaction of drugs with lysosomal lipid-
degrading enzymes leading to enzyme inactiva-
tion (6,19,32,39); interaction between the drugs
and lipids leading to an alteration in physico-
chemical properties of the lipid (2,3,6,8,32,39).
The last possibility has gained the most support.
The molecules of chlorphentermine, triparanol
and of the other drugs mentioned earlier have
amphophilic character (3,7,8). One part of the
molecule contains protonated nitrogen and has
hydrophilic properties. The aromatic portion of
the molecule, particularly with certain substitu-
tions on the ring, is hydrophobic. The ampho-
philia of the drugs facilitates complex formation
with amphophilic phospholipids (3). An interac-
tion between chlorphentermine and phospholip-
ids has been demonstrated by nuclear magnetic
resonance studies (40).
It is believed that the formation of a complex
between the drug and the phospholipid leads to
an alteration in physicochemical properties of the
phospholipid and impairs its metabolism in phag-
osomes and in lysosomes (2, 3, 40). In the lung the
drugs bind to phospholipids such as dipalmitoyl
lecithin of pulmonary secretions in granular
pneumocytes. These secretions are released into
alveolar lumina, where they are taken up by pul-
monary macrophages. Because of impaired diges-
tion, the secretions persist and accumulate, and
the macrophages become foam cells. Similar drug
binding occurs in various cells in the body. The
drugs react with phospholipids of cellular mem-
branes and the altered membranes are removed
by autophagy. The sequestered proteins and car-
bohydrates are broken down by lysosomal en-
zymes while the drug-lipid complexes resist di-
gestion and are transformed into myeloid mem-
branes. Thus a myeloid body is formed. For these
reasons, the formation of foam cells and of mye-
loid bodies can be considered a drug-induced
lysosomal disease (28) or a drug-induced gener-
alized phospholipidosis (6-8).
The drug-induced lipidoses are side effects of
drugs and do not depend on the pharmacological
actions ofthe drugs (8). The anorectic drugs have
been associated with pulmonary hypertension in
man. These vascular effects are related to an
~aRepe4 metabolism of serotonin rather than to
foam cell accumulation (41). The accumulation of
pulmonary foam cells and of myeloid bodies may,
however, be associated with serious clinical prob-
lems. Functional impairment of overloaded mac-
Environmental Health Perspectives 116rophages may lead to a decreased resistance to
bacterial and fungal infections (21). Massive ac-
cumulation of myeloid bodies may cause cellular
damage and death. Administration ofchloroquine
has been associated with retinopathy in man (42).
Hyperlipidemia, hepatosplenomegaly, liver cell
necrosis and cirrhosis have been reported in pa-
tients treated with diethylaminoethoxyhexestrol
(19,26,43).
Side effects of some of the discussed drugs
were discovered only after they were used in
men. Most probably other drugs will have similar
side effects (44). It is therefore imperative to
search for myeloid body formation when new
drugs are introduced. In animal experiments,
massive accumulation of pulmonary foam cells is
an excellent indicator of a drug-induced lipidosis.
It should be remembered, however, that foam
cells occur in other pathological entities (1) and in
old normal rats (45). In clinical trials the
peripheral blood is easily accessible for ultra-
structural studies. Lymphocytes and plasma cells
respond to amphophilic drugs by formation of
myeloid bodies in animals and in man (12,23,28).
The intra-alveolar accumulation of foamy mac-
rophages is a form of pulmonary histiocytosis
(2,15). Massive accumulation of intra-alveolar
histiocytes and hyperplasia of granular pneumo-
cytes are found also in human and experimental
desquamative interstitial pneumonia (46-51). The
macrophages are, however, smaller, lack foamy
appearance, and contain PAS-positive granules.
Necrosis is absent.
Administration of busulfan, hexamethonium,
apresoline and antituberculous drugs may be
associated with hypertrophy of granular pneu-
mocytes. The essential feature of the "busulfan
lung" is chronic pulmonary fibrosis and does not
resemble lesions induced by amphopilic drugs
(52-54).
The drug-induced pulmonary lipidosis (15) and
desquamative pneumonia in man (55) may pro-
gress to alveolar proteninosis. The alveoli in
alveolar proteinosis are filled with amorphous,
protainaceous, PAS-positive material which is
rich in lipids and contains phospholipids (56-58).
For this reason the term alveolar lipo-proteinosis
is more exact (58). The intra-alveolar material is
mostly derived from disintegrated macrophages
(59) and pneumocytes (57,58,60). Alveolar pro-
teinosis is observed in acute silicosis (20,60,61)
and as a response to a variety of nonspecific
chemical irritants (59).
In summary, the drug-induced pulmonary his-
tiocytosis is a manifestation of a generalized
drug-induced lysosomal storage disease (or lip-
idosis). The use of the electron microscope great-
ly facilitates the search for drug-induced side ef-
fects at the cellular level.
This study was supported in part by Cancer Research
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